449 related articles for article (PubMed ID: 27210871)
21. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
Chen HF; Hou J; Yuan ZG; Wang DX; Fu WJ; Chen YB
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):113-6. PubMed ID: 18681313
[TBL] [Abstract][Full Text] [Related]
22. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
23. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
24. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
25. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
26. [Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].
Zhu W; Lu J; Lu J; Hou J; Huang X; Chen W
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):741-4. PubMed ID: 26080844
[TBL] [Abstract][Full Text] [Related]
27. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
28. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
29. Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Tacchetti P; Rocchi S; Zamagni E; Barbato S; Rizzello I; De Cicco G; Pantani L; Mancuso K; Fusco A; Dozza L; Ursi M; Favero E; Terragna C; Testoni N; Cavo M
Am J Hematol; 2022 Dec; 97(12):1607-1615. PubMed ID: 36198076
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
31. Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin.
Jia Z; Xia J; Lu Q
Lab Med; 2023 Dec; ():. PubMed ID: 38141202
[TBL] [Abstract][Full Text] [Related]
32. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
33. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
34. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
Rifkin RM; Abonour R; Terebelo H; Shah JJ; Gasparetto C; Hardin J; Srinivasan S; Ricafort R; Nagarwala Y; Durie BG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):368-76. PubMed ID: 25617035
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of serum free light chain in patients with multiple myeloma].
Zhang SS; Wu S; Qu XY; Xu J; Liu P; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):930-5. PubMed ID: 23998588
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.
Batinić J; Perić Z; Šegulja D; Last J; Prijić S; Dubravčić K; Volarić L; Sertić D; Radman I; Bašić-Kinda S; Matišić D; Batinić D; Labar B; Nemet D
Croat Med J; 2015 Jun; 56(3):263-71. PubMed ID: 26088851
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
[TBL] [Abstract][Full Text] [Related]
39. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.
Abbi KK; Silverman M; Farooq U; Tricot A; Dozeman L; Nadiminti K; Krasowski MD; Tricot GJ
Br J Haematol; 2016 Aug; 174(4):536-40. PubMed ID: 27172326
[TBL] [Abstract][Full Text] [Related]
40. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
Dejoie T; Corre J; Caillon H; Hulin C; Perrot A; Caillot D; Boyle E; Chretien ML; Fontan J; Belhadj K; Brechignac S; Decaux O; Voillat L; Rodon P; Fitoussi O; Araujo C; Benboubker L; Fontan C; Tiab M; Godmer P; Luycx O; Allangba O; Pignon JM; Fuzibet JG; Legros L; Stoppa AM; Dib M; Pegourie B; Orsini-Piocelle F; Karlin L; Arnulf B; Roussel M; Garderet L; Mohty M; Meuleman N; Doyen C; Lenain P; Macro M; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H
Blood; 2016 Dec; 128(25):2941-2948. PubMed ID: 27729323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
